To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Evaluation of the safety … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses

Journal article
Authors M. Akhtar
M. I. Chowdhury
T. R. Bhuiyan
Joanna Kaim
T. Ahmed
T. A. Rafique
A. Khan
S. I. A. Rahman
F. Khanam
Y. A. Begum
M. Z. Sharif
L. N. Islam
N. Carlin
N. Maier
A. Fix
T. F. Wierzba
R. I. Walker
A. L. Bourgeois
Ann-Mari Svennerholm
F. Qadri
Anna Lundgren
Published in Vaccine
Volume 37
Issue 37
Pages 5645-5656
ISSN 0264-410X
Publication year 2019
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Pages 5645-5656
Language en
Keywords ETEC, Vaccine, Antibodies in lymphocyte supernatant, Antibody-secreting cell, IgA, Adult, ELISA, antibody-secreting cell, b-subunit vaccine, intestinal immune-responses, developing-countries, cholera vaccination, etec vaccine, colonization, factors, infants, mucosal, humans, Immunology
Subject categories Microbiology in the medical area, Immunology in the medical area


The safety and immunogenicity of the second generation oral enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX, consisting of inactivated recombinant E. coli strains over-expressing the colonization factors (CFs) CFA/I, CS3, CS5 and CS6 and the heat labile toxoid LCTBA, were evaluated in Bangladeshi volunteers. To enable analysis of antibody responses against multiple vaccine antigens for subsequent use in small sample volumes from children, a sensitive electrochemiluminescence (ECL) assay for analysis of intestine-derived antibody-secreting cell responses using the antibodies in lymphocyte secretions (ALS) assay was established using Meso Scale Discovery technology. Three groups of Bangladeshi adults (n = 15 per group) received two oral doses of ETVAX with or without double mutant LT (dmLT) adjuvant or placebo in the initial part of a randomized, double-blind, placebo-controlled, age-descending, dose-escalation trial. CF- and LTB-specific ALS and plasma IgA responses were analyzed by ECL and/or ELISA. ETVAX was safe and well tolerated in the adults. Magnitudes of IgA ALS responses determined by ECL and ELISA correlated well (r = 0.85 to 0.98 for the five primary antigens, P < 0.001) and ECL was selected as the ALS readout method. ALS IgA responses against each of the primary antigens were detected in 87-100% of vaccinees after the first and in 100% after the second vaccine dose. Plasma IgA responses against different CFs and LTB were observed in 62-93% and 100% of vaccinees, respectively. No statistically significant adjuvant effect of dmLT on antibody responses to any antigen was detected, but the overall anti-genic breadth of the plasma IgA response tended to favor the adjuvanted vaccine when responses to 4 or more or 5 vaccine antigens were considered. Responses in placebo recipients were infrequent and mainly detected against single antigens. The promising results in adults supported testing ETVAX in descending age groups of children.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?